Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Sales and Divestitures (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Gains from Sales and Divestitures data on record, last reported at $1.5 million in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 4.37% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 4.37%, while the annual FY2025 figure was $1.5 million, 4.37% up from the prior year.
  • Gains from Sales and Divestitures reached $1.5 million in Q4 2025 per ACRS's latest filing, up from $608833.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.5 million in Q4 2025 and bottomed at $377371.0 in Q1 2021.
  • Average Gains from Sales and Divestitures over 5 years is $761333.8, with a median of $568940.5 recorded in 2024.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 60.89% in 2022, then surged 97.69% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $1.3 million in 2021, then crashed by 60.21% to $533212.0 in 2022, then soared by 39.77% to $745279.0 in 2023, then soared by 97.69% to $1.5 million in 2024, then rose by 4.37% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.5 million in Q4 2025, $608833.0 in Q3 2025, and $595035.0 in Q2 2025.